Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Citigroup Upgrades Integra Lifesciences to Neutral, Maintains Price Target to $38

Author: Benzinga Newsdesk | April 03, 2024 11:30am

Citigroup analyst Joanne Wuensch upgrades Integra Lifesciences (NASDAQ:IART) from Sell to Neutral and maintains the price target from $38 to $38.

Posted In: IART